Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EPS (Basic): 2016-2025

Historic EPS (Basic) for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to $0.00.

  • Akebia Therapeutics' EPS (Basic) rose 102.04% to $0.00 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.08, marking a year-over-year increase of 66.03%. This contributed to the annual value of -$0.33 for FY2024, which is 17.86% down from last year.
  • Latest data reveals that Akebia Therapeutics reported EPS (Basic) of $0.00 as of Q3 2025, which was up 116.55% from $0.00 recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' EPS (Basic) ranged from a high of $0.16 in Q2 2022 and a low of -$0.51 during Q2 2021.
  • In the last 3 years, Akebia Therapeutics' EPS (Basic) had a median value of -$0.06 in 2023 and averaged -$0.05.
  • In the last 5 years, Akebia Therapeutics' EPS (Basic) plummeted by 3,475.05% in 2024 and then soared by 133.33% in 2025.
  • Akebia Therapeutics' EPS (Basic) (Quarterly) stood at -$0.40 in 2021, then skyrocketed by 90.00% to -$0.04 in 2022, then soared by 108.15% to $0.00 in 2023, then crashed by 3,475.05% to -$0.11 in 2024, then surged by 102.04% to $0.00 in 2025.
  • Its EPS (Basic) was $0.00 in Q3 2025, compared to $0.00 in Q2 2025 and $0.03 in Q1 2025.